Prosight Management’s Rein Therapeutics RNTX Stock Holding History

Prosight Management’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Buy	1,100,000 +688,400	+167%	+$833K	0.2%	34
2026 Q1	$535K	Sell	411,600 -31,000	-7%	-$38.5K	0.09%	45
2025 Q4	$513K	Sell	442,600 -125,298	-22%	-$173K	0.11%	38
2025 Q3	$650K	Buy	567,898 +139,979	+33%	+$178K	0.15%	38
2025 Q2	$599K	Sell	427,919 -2,081	-0.5%	-$3.75K	0.15%	36
2025 Q1	$761K	Buy	430,000 +25,021	+6%	+$52.5K	0.25%	35
2024 Q4	$931K	Buy	404,979 +32,822	+9%	+$99.4K	0.26%	34
2024 Q3	$1.32M	Buy	372,157 +107,157	+40%	+$286K	0.32%	38
2024 Q2	$734K	Buy	+265,000	New	+$1.09M	0.22%	43

Other funds holding RNTX

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Prosight Management's RNTX Position: Q2 2026 in Review

Prosight Management increased its Rein Therapeutics (RNTX) stake by 167% in Q2 2026, buying an estimated $833K and bringing the position to 1,100,000 shares worth $1.14M. The position accounts for 0.2% of the portfolio, ranked #34.

Prosight Management first reported a position in RNTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.32M in Q3 2024. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

Prosight Management held 1,100,000 shares of Rein Therapeutics worth $1.14M as of Q2 2026.
Prosight Management bought 688,400 Rein Therapeutics shares in Q2 2026, an estimated $833K.
Rein Therapeutics made up 0.2% of Prosight Management's portfolio in Q2 2026, its #34 holding.
Prosight Management first reported a position in Rein Therapeutics in Q2 2024 and has held it in 9 quarters since.
Prosight Management's Rein Therapeutics position peaked at $1.32M in Q3 2024.
60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.